A. Edward Yen, MD, presented “Highlights from GU ASCO and ASCO 2024” during the 28th Annual Innovations in Urologic Practice conference on September 22, 2024, in Denver, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Yen, A. Edward. “Highlights from GU ASCO and ASCO 2024.” September 22, 2024. Accessed Nov 2024 . https://grandroundsinurology.com/highlights-from-gu-asco-and-asco-2024/
Highlights from GU ASCO and ASCO 2024 – Summary
A. Edward Yen, MD, reviews recent developments in prostate cancer treatment, summarizing key trials from recent oncology meetings. He begins this 29-minute presentation by outlining the evolving treatment landscape, from localized to metastatic castration-resistant prostate cancer. The focus narrows on select phase II and III trials involving novel therapeutics and treatment strategies.
Dr. Yen begins with the BRCAAway trial, which explores abiraterone, olaparib, and their combination in patients with metastatic CRPC harboring BRCA1/2 or ATM mutations. He then moves on to the Contact-02 study, which investigates cabozantinib and atezolizumab versus second-line hormonal therapy in metastatic CRPC patients. Continuing, he shares the results of the Embark study, which examined enzalutamide with or without androgen deprivation therapy in patients with non-metastatic CRPC.
Other notable studies include a negative evaluation of metformin for preventing progression in low-risk prostate cancer and an exploratory phase I trial of a novel human kallikrein-targeted radioligand therapy. Dr. Yen concludes with an overview of ARV-766, a PROTAC androgen receptor degrader showing strong PSA responses, highlighting its potential for future development in targeting resistant androgen receptor mutations in advanced CRPC.
About The 28th Annual Innovations in Urologic Practice:
Presented by co-chairs Mohit Khera, MD, MBA, MPH, and Michael Coburn, MD, FACS, the Innovations in Urologic Practice conference provides a detailed review and commentary on multiple genitourinary and urologic diseases. Among the featured oncological topics are bladder cancer and immunotherapies, as well as upper tract cancer management, prostate cancer, including state-of-the-art imaging, focal therapy, and MRI. Experts also discuss new tools and techniques for nephrectomy and treating advanced renal cell carcinoma. In terms of general urological approaches, the conference also includes pelvic reconstruction and trauma; men’s health topics like male infertility, andrology, and sexual dysfunction; OAB and voiding dysfunctions; and ways to diagnose and treat infections in the urology patient.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
A. Edward Yen, MD, is an assistant professor of medicine in the hematology and oncology section at Baylor College of Medicine in Houston, Texas. He is a practicing genitourinary medical oncologist at the Dan L Duncan Comprehensive Cancer Center and the Bladder Cancer Center at Baylor He is also affiliated with Baylor St. Luke’s Medical Center and the Houston VA Medical Center Hospital. Dr. Yen earned his MD from Baylor College of Medicine. His research on androgen receptors in hormone-dependent and castration-resistant prostate cancer has been published in Pharmacology & Therapeutics. His professional interests include prostate and genitourinary cancers.